All In Biotech

Drug Trial Radar · NCT04348383

Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome

Last checked: Nov 20, 2026Latest source record: Jun 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Apr 8, 2020

Primary completion

Feb 28, 2023

Study completion Feb 28, 2023

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio), expected to decrease inflammation and expression of adhesion molecules in the endothelium, leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance through a change in the Cytokine balance, which is decisive in preventing multiorgan failure and death in patients with SARS-CoV-2 infection with clinical status grade 4 or 5 according to the WHO classification

Conditions

  • COVID19

Interventions

  • DefibrotideDrug

    6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days

  • PlaceboDrug

    Placebo 250 cc every 6 hours for 7 or15 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical improvement.Time frame: 7,15, 30 day

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Clinico y Provincial de Barcelona

    Barcelona, Spain

  • Virgen de la Arrixaca University Clinical Hospital

    Murcia, Spain

  • Hospital General Universitario Morales Meseguer

    Murcia, Spain

  • Hospital General Universitario Reina Sofía

    Murcia, Spain

  • Hospital Universitario Salamanca

    Salamanca, Spain

  • Hospital General Universitario Santa Lucía

    Cartagena, Murcia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.